Abstract
Purine nucleoside analogues are extensively used in the treatment of malignancies and viral diseases. For example, cladribine and fludarabine are two purine nucleoside analogues that have activity in the treatment of chronic lymphocytic leukemias. These chemotherapeutic agents exert their cytotoxic actions through interactions with intracellular targets. Due to their hydrophilic nature, many purine nucleoside analogues do not readily diffuse across cell membranes at therapeutic concentrations. The presence or absence of mediated transport systems will therefore have an impact on their pharmacological activities. There are two families of nucleoside transporters with members in human (h) cells and tissues: the equilibrative nucleoside transporters (hENTs) and the concentrative nucleoside transporters (hCNTs). These transporter proteins mediate the uptake of both physiologic nucleosides and nucleoside analogue chemotherapeutic agents. It has been documented that permeant specificity, tissue distribution and cellular localization of these transporters contribute to the antineoplastic activity of the purine nucleoside analogues. This article will review current knowledge of the role of nucleoside transport proteins in the cytotoxic actions of purine nucleoside analogues.
Keywords: Anti-cancer purine nucleoside analogues, nucleoside transporters
Current Cancer Therapy Reviews
Title: The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents
Volume: 4 Issue: 1
Author(s): Carol E. Cass and Karen M. King
Affiliation:
Keywords: Anti-cancer purine nucleoside analogues, nucleoside transporters
Abstract: Purine nucleoside analogues are extensively used in the treatment of malignancies and viral diseases. For example, cladribine and fludarabine are two purine nucleoside analogues that have activity in the treatment of chronic lymphocytic leukemias. These chemotherapeutic agents exert their cytotoxic actions through interactions with intracellular targets. Due to their hydrophilic nature, many purine nucleoside analogues do not readily diffuse across cell membranes at therapeutic concentrations. The presence or absence of mediated transport systems will therefore have an impact on their pharmacological activities. There are two families of nucleoside transporters with members in human (h) cells and tissues: the equilibrative nucleoside transporters (hENTs) and the concentrative nucleoside transporters (hCNTs). These transporter proteins mediate the uptake of both physiologic nucleosides and nucleoside analogue chemotherapeutic agents. It has been documented that permeant specificity, tissue distribution and cellular localization of these transporters contribute to the antineoplastic activity of the purine nucleoside analogues. This article will review current knowledge of the role of nucleoside transport proteins in the cytotoxic actions of purine nucleoside analogues.
Export Options
About this article
Cite this article as:
Cass E. Carol and King M. Karen, The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents, Current Cancer Therapy Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339408783565501
DOI https://dx.doi.org/10.2174/157339408783565501 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Role of the Renin-Angiotensin System in Gynecologic Cancers
Current Cancer Drug Targets Modified Envelope Glycoproteins to Retarget Retroviral Vectors
Current Gene Therapy Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology The Role of Trophoblast Nutrient and Ion Transporters in the Development of Pregnancy Complications and Adult Disease
Current Vascular Pharmacology Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Leptin, Estrogens and Cancer
Mini-Reviews in Medicinal Chemistry CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets Modulation of ABC Transporters by Nuclear Receptors: Physiological, Pathological and Pharmacological Aspects
Current Medicinal Chemistry The Challenge of Exploiting ABCG2 in the Clinic
Current Pharmaceutical Biotechnology Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers
Medicinal Chemistry Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Membrane Fusion Mediated Targeted Cytosolic Drug Delivery Through scFv Engineered Sendai Viral Envelopes
Current Molecular Medicine Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Current Status and Future Perspective for Research on Medicinal Plants with Anticancerous Activity and Minimum Cytotoxic Value
Current Drug Targets